NCT07191964

Brief Summary

This randomized controlled trial evaluates the additive effect of Supra-Sartorial Subcutaneous Infiltration (SSSI) when performed in combination with intermittent adductor canal block (iACB) and posterior capsule local infiltration analgesia (PC-LIA) for pain management after total knee arthroplasty (TKA). SSSI, an easy-to-perform tentative proxy block to targeted anterior femoral cutaneous nerve (AFCN) block, is tested in 90 adults (45-90 years) randomized into two arms: active SSSI versus sham SSSI. Primary outcome is pain scores at rest and during movement on postoperative day 0; secondary outcomes include daily pain trajectory at rest and during movement, functional recovery scores, rescue analgesic doses over days 0-3, and quality of recovery assessment on day 4.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
13mo left

Started Aug 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 10, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 25, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

July 1, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

September 10, 2025

Last Update Submit

June 29, 2026

Conditions

Keywords

Anterior Femoral Cutaneous Nerve BlockTotal Knee Arthroplasty

Outcome Measures

Primary Outcomes (1)

  • Pain: VAS at rest and during movement on postoperative day 0

    VAS pain scores at rest and during continuous passive motion will be taken on postoperative day 0 at 9 PM. Higher VAS pain scores indicate worse pain levels.

    at 9 PM on postoperative day 0

Secondary Outcomes (6)

  • Pain: VAS at rest and during movement from postoperative day 1-4

    From postoperative day 1 at 6 AM to postoperative day 4 at 6 AM.

  • Rescue ACB doses (0.3% ropivacaine, mg)

    From the time discharging from post-anesthesia care unit to postoperative day 4 at 6 AM

  • Additional morphine doses (mg)

    From the time discharging from post-anesthesia care unit to postoperative day 4 at 6 AM

  • Functional: TUG test

    From postoperative day 1 at 6 AM to postoperative day 4 at 6 AM.

  • Functional: CPM maximal allowable angle

    From postoperative day 0 at 9 PM to day 3 at 6 PM.

  • +1 more secondary outcomes

Study Arms (2)

SSSI (active) + iACB and PC-LIA

ACTIVE COMPARATOR
Procedure: Supra-Sartorial Subcutaneous Infiltration (SSSI)Procedure: intermittent adductor canal block (iACB)Procedure: posterior capsule local infiltration analgesia (PC-LIA)

SSSI (sham) + iACB and PC-LIA

PLACEBO COMPARATOR
Procedure: Supra-Sartorial Subcutaneous Infiltration (SSSI)Procedure: intermittent adductor canal block (iACB)Procedure: posterior capsule local infiltration analgesia (PC-LIA)

Interventions

20 mL Ropivacaine or saline infiltrated subcutaneously from lateral to medial, superficial to vastus medialis and sartorius muscle, at femoral triangle apex using inject-as-you-advance technique, avoiding hyperechoic nerves.

SSSI (active) + iACB and PC-LIASSSI (sham) + iACB and PC-LIA

A single-shot adductor canal block is first performed post-operatively with 20 mL 0.3% Ropivacaine at the level of femoral triangle apex before inserting a catheter into the canal. The following doses (20 mL each time) start at 9:00 PM on the day of surgery and are intermittently given every 12 hours until day 4.

SSSI (active) + iACB and PC-LIASSSI (sham) + iACB and PC-LIA

PC-LIA consists of two 10 mL injections of 0.3% ropivacaine delivered intraoperatively to the posteromedial and posterolateral aspects of the posterior capsule before cementation. The target injection plane is the potential space between the posterior capsule and the popliteal artery.

SSSI (active) + iACB and PC-LIASSSI (sham) + iACB and PC-LIA

Eligibility Criteria

Age45 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 45-90 undergoing unilateral primary TKA for osteoarthritis.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Able to provide informed consent and use NRS pain scales.
  • Surgery scheduled to start before noon to standardize spinal anesthesia recovery.

You may not qualify if:

  • Bilateral or revision TKA.
  • Contraindications to regional anesthesia (e.g., coagulopathy, infection at injection site).
  • Chronic opioid use (\>30 mg morphine equivalents/day) or preoperative NRS \>4.
  • Pre-existing neurological deficits in lower extremities or AFCN-related neuropathy.
  • Allergy to ropivacaine.
  • Pregnancy, breastfeeding, or cognitive impairment affecting assessments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taipei Municipal Wanfang Hospital

Taipei, 116, Taiwan

Location

Related Publications (6)

  • Yeoh SR, Chang WC, Wang KL, Tai KY, Hsu FK, Chuang CW. Supra-Sartorial Subcutaneous Infiltration (SSSI) for Anterior Femoral Cutaneous Nerve Coverage in Total Knee Arthroplasty: A Preliminary Clinical Study. Biomedicines. 2025 Sep 27;13(10):2368. doi: 10.3390/biomedicines13102368.

    PMID: 41153655BACKGROUND
  • Kampitak W, Tanavalee A, Tansatit T, Ngarmukos S, Songborassamee N, Vichainarong C. The analgesic efficacy of anterior femoral cutaneous nerve block in combination with femoral triangle block in total knee arthroplasty: a randomized controlled trial. Korean J Anesthesiol. 2021 Dec;74(6):496-505. doi: 10.4097/kja.21120. Epub 2021 Jun 29.

    PMID: 34182749BACKGROUND
  • Pivec C, Bodner G, Mayer JA, Brugger PC, Paraszti I, Moser V, Traxler H, Riegler G. Novel Demonstration of the Anterior Femoral Cutaneous Nerves using Ultrasound. Ultraschall Med. 2018 Feb 7. doi: 10.1055/s-0043-121628. Online ahead of print.

    PMID: 29415312BACKGROUND
  • Bjorn S, Nielsen TD, Jensen AE, Jessen C, Kolsen-Petersen JA, Moriggl B, Hoermann R, Bendtsen TF. The Anterior Branch of the Medial Femoral Cutaneous Nerve Innervates Cutaneous and Deep Surgical Incisions in Total Knee Arthroplasty. J Clin Med. 2024 May 31;13(11):3270. doi: 10.3390/jcm13113270.

    PMID: 38892981BACKGROUND
  • Bjorn S, Nielsen TD, Jensen AE, Jessen C, Kolsen-Petersen JA, Moriggl B, Hoermann R, Nyengaard JR, Bendtsen TF. The anterior branch of the medial femoral cutaneous nerve innervates the anterior knee: a randomized volunteer trial. Minerva Anestesiol. 2023 Jul-Aug;89(7-8):643-652. doi: 10.23736/S0375-9393.22.16910-5. Epub 2023 Feb 27.

    PMID: 36852567BACKGROUND
  • Bjorn S, Nielsen TD, Moriggl B, Hoermann R, Bendtsen TF. Anesthesia of the anterior femoral cutaneous nerves for total knee arthroplasty incision: randomized volunteer trial. Reg Anesth Pain Med. 2019 Dec 10:rapm-2019-100904. doi: 10.1136/rapm-2019-100904. Online ahead of print.

    PMID: 31826920BACKGROUND

Central Study Contacts

Shang-Ru Yeoh, MD, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2025

First Posted

September 25, 2025

Study Start

August 1, 2026

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

July 1, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations